EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open access · CC BY-NC-ND 4.0

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials

Maria Buti iD, Young-Suk Lim iD, Henry Lik Yuen Chan, Kosh Agarwal, Patrick Marcellin, Maurizia R Brunetto, Wan-Long Chuang, Harry L A Janssen, Scott K Fung, Namiki Izumi, Maciej S Jablkowski, Dzhamal Abdurakhmanov and 11 more

Alimentary Pharmacology & Therapeutics · 2024-12 · 60 (11-12) · 1573-1586

DOI: 10.1111/apt.18278 ↗

At a glance

Randomisierte kontrollierte Studie in Alimentary Pharmacology & Therapeutics, published online on 2024-09-27. Written by Maria Buti and 22 co-authors. Institution: Hospital Universitario Vall d'Hebron, Barcelona, Spain. Major MEDLINE topics: Tenofovir, Hepatitis B, Chronic, Alanine, Antiviral Agents. Cited 42 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Gilead Sciences.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

In two phase 3 studies, tenofovir alafenamide (TAF) showed non‐inferior efficacy versus tenofovir disoproxil fumarate (TDF), with more favourable renal and bone safety in patients with chronic hepatitis B (CHB).

Aims

Here, we report the studies' final 8‐year results.

Methods

CHB patients (hepatitis B e antigen [HBeAg]‐negative and HBeAg‐positive) were randomised (2:1) to double‐blind TAF 25 mg/day or TDF 300 mg/day for up to 3 years, followed by open‐label (OL) TAF through year 8. Virological, biochemical, serological and fibrosis responses, and safety, including bone and renal parameters, were evaluated. Resistance to TAF was assessed annually by deep sequencing of polymerase/reverse transcriptase and by phenotyping.

Results

Among 1298 patients randomised to double‐blind TAF ( n = 866) or double‐blind TDF ( n = 432), 775 in the TAF group and 382 in the TDF group received OL TAF, including 180 and 202 who switched from TDF to TAF at year 2 (TDF2y → TAF6y) or year 3 (TDF3y → TAF5y), respectively. At year 8, among patients in the TAF8y, TDF2y → TAF6y and TDF3y → TAF5y groups, 69%, 66% and 73% (missing‐equals‐failure analysis) and 95%, 94% and 97% (missing‐equals‐excluded) of patients, respectively, achieved HBV DNA

Subjects

MeSH terms (MEDLINE)

TenofovirHepatitis B, ChronicAlanineAntiviral AgentsAdenineHumansMaleFemaleDouble-Blind MethodAdultMiddle AgedTreatment OutcomeHepatitis B virusDrug Resistance, ViralHepatitis B e Antigens

Substances

Tenofovirtenofovir alafenamideAlanineAntiviral AgentsAdenineHepatitis B e Antigens

Authors and institutions

  • Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • CIBEREHD del Instituto Carlos III, Madrid, Spain.
  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Faculty of Medicine, The Chinese University of Hong Kong, HMA Office, Tai Wai, Shatin, Hong Kong.
  • Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK.
  • Hepatology Department, Hôpital Beaujon, APHP, INSERM, University of Paris, Clichy, France.

ORCID profiles: Maria Buti, Young-Suk Lim, Leland J Yee, Wai-Kay Seto

Funding

  • Gilead Sciences

Cite

APA

Buti, M., Lim, Y. S., Chan, H. L. Y., Agarwal, K., Marcellin, P., Brunetto, M. R., Chuang, W. L., Janssen, H. L. A., Fung, S. K., Izumi, N., Jablkowski, M. S., Abdurakhmanov, D., Abramov, F., Wang, H., Botros, I., Yee, L. J., Mateo, R., Flaherty, J. F., Osinusi, A., …, & Gane, E. J. (2024). Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials. Alimentary Pharmacology & Therapeutics, 60(11-12), 1573-1586. https://doi.org/10.1111/apt.18278

Vancouver

Buti M, Lim YS, Chan HLY, Agarwal K, Marcellin P, Brunetto MR, et al. Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials. Alimentary Pharmacology & Therapeutics. 2024;60(11-12):1573-1586. doi:10.1111/apt.18278

BibTeX
@article{Buti2024,
  author = {Buti, Maria and Lim, Young-Suk and Chan, Henry Lik Yuen and Agarwal, Kosh and Marcellin, Patrick and Brunetto, Maurizia R and Chuang, Wan-Long and Janssen, Harry L A and Fung, Scott K and Izumi, Namiki and Jablkowski, Maciej S and Abdurakhmanov, Dzhamal and Abramov, Frida and Wang, Hongyuan and Botros, Irina and Yee, Leland J and Mateo, Roberto and Flaherty, John F and Osinusi, Anu and Pan, Calvin Q and Shalimar, X and Seto, Wai-Kay and Gane, Edward J},
  title = {Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {60},
  number = {11-12},
  pages = {1573--1586},
  doi = {10.1111/apt.18278}
}
Start for free →